YL 211
Alternative Names: YL-211Latest Information Update: 24 May 2024
At a glance
- Originator MediLink Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 May 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT06384352)
- 02 Jan 2024 YL 211 licensed to Roche worldwide for the treatment of Solid tumours
- 02 Jan 2024 Preclinical trials in Solid tumours in China (Parenteral), prior to January 2024